Fortrea Holdings Inc. (FTRE) - Stock Analysis

Last updated: Apr 4, 2026

HealthcareClosed

Research Idea

Research content for general circulation. Not individualized advice. Methodology & Disclosures

Fortrea displays strong operational momentum with raised revenue and backlog, cost savings, debt reductions, and a significant 50% rally in 3 weeks; however, margin compression, leverage, legal risk, and overextension temper conviction, requiring active risk management.

Loading chart data...

Idea window: 12/4/2025 – 12/11/2025Sector: Healthcare

AI Analyst Overview

Last Price
$9.38
Market Cap
$877.03M
1D Return
-2.60%
YTD Return
-45.62%

Loading chart data...

Valuation Metrics

P/E
-0.9
P/B
1.5
P/S
0.3
EV/EBITDA
-1.2
Div Yield
—

Fundamental Analysis

6.0

Key Financial Insights: • Positive free cashflow • High leverage • Negative net margins Despite strong gross margins and positive free cash flow, FTRE remains unprofitable with heavy OPEX-driven losses, high leverage and tight liquidity that materially raise risk even as quarterly EBITDA improves.

risk
valuation

Price Behavior

6.0

Key Price Behavior Insights: • Neutral momentum • Tight consolidation • Clear stop reference Support Level: $8.90 Resistance Level: $9.90–$9.95 Over the last month FTRE has traded flat around the last-month SMA near $9.46, consolidating above support ~$8.90 with resistance at ~$9.90–$9.95—indicating range-bound action unless a clear breakout or breakdown occurs while it remains well below January–February peaks (~$16–$17.5).

rangebound
downtrend

Sentiment & News

5.0

Key News Insights: • Institutional selling • RSU hiring incentive • March concentration Institutional investors sharply trimmed FTRE positions in March while the company granted 130,000 RSUs to new hires, signalling simultaneous external selling pressure and internal talent-focused equity incentives.

rebalancing
talenthire
AI

AI Summary

6.0
Neutral

Fortrea has shifted from a growth/multiple story to a cash‑and‑deleveraging replay—equity upside now hinges on sustaining positive FCF, converting deferred revenue/backlog at stable gross margins, and materially reducing net debt over 12–18 months. Key risk: high leverage and sub‑1 current ratio mean any slip in cash conversion, missed EBITDA targets, or a major client slowdown would likely force dilutive financing or a sharp equity re‑rating.

CashGeneration
Leverage
Execution
AI summary updated 5 days ago

Description

Fortrea Holdings Inc. is a contract research organization that provides development services for biopharmaceuticals and medical devices globally. Its operations are organized into Clinical Services, covering clinical pharmacology and the spectrum of clinical development, and Enabling Services, which supplies patient access, trial technology, randomization and drug supply support. The company delivers these capabilities through full-service, functional service provider and hybrid models and also offers phase I–IV trial management and post-approval support; it was incorporated in 2023 and is based in Durham, North Carolina.

Idea History

DateCloseTickerCompanySummaryStatusP/L
Dec 4Dec 11FTREFortrea Holdings Inc.
Fortrea displays strong operational momentum with raised revenue and backlog, cost savings, debt reductions, and a significant 50% rally in 3 weeks; however, margin compression, leverage, legal risk, and overextension temper conviction, requiring active risk management.
Closed+7.2%
Research content for educational purposes only. Not investment advice. All decisions are your responsibility.